Table 2 Combination of anti-PfCSP and anti-PfTRAP can improve sterile protection from mosquito-bite challenge.

From: Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and may enhance protection of anti-CSP monoclonal antibodies

 

Sterile protectiona Exp 1

Sterile protectiona Exp 2

Sterile protectiona Exp 3

Sterile protectiona Combined

Comparison p valueb vs. 150 µg mIgG

Comparison p valueb vs. 50 µg αCSP

150 μg mIgGc

0/7 (0%)d

0/7 (0%)d

0/5 (0%)

0/19 (0%)

–

<0.0001

50 μg AKBR-4

0/6 (0%)

–

0/5 (0%)

0/11 (0%)

1

0.0002

50 μg αCSP

5/7 (71%)d

5/8 (63%)d

5/8 (63%)

15/23 (65%)

<0.0001

–

150 μg αCSP

–

3/5 (60%)

–

3/5 (60%)

0.002

0.88

50 μg AKBR-4 + 50 μg αCSP

–

6/7 (86%)

8/9 (89%)

14/16 (88%)

<0.0001

0.131

  1. aSterile protection: mice that remain parasite-free (via microscopic blood-smear monitoring) throughout the experimental time course.
  2. bBarnard’s exact test p values shown were not adjusted for multiple comparisons due to small group sizes and a small number of predefined comparisons being made.
  3. cmIgG: normal mouse IgG control
  4. dindicates results previously reported in Kisalu et al.55.
  5. Mice were injected with indicated doses of either nonspecific mIgG, anti-CSP mAb CIS43, anti-PfTRAP mAb AKBR-4, or a combination of anti-CSP and AKBR-4 24 h prior to challenge with five Pf-infected mosquitoes. Mice were injected with human red blood cells on days 5 and 6, and then blood was sampled on days 7 and 9 to detect blood-stage parasitemia by qRT-PCR. The number and percentages of mice protected across three independent experiments are shown.
Back to article page